API
< Back to all clusters
[BUSINESS] · United States · 2 sources

started · updated

Eli Lilly sees increased institutional investment and pipeline growth

Eli Lilly and Company continues to see significant institutional interest and pipeline development. Recent SEC filings show several firms increasing their stakes during the third quarter, including RVW Wealth LLC, which raised its position by 93.8%, and Violich Capital Management Inc., which increased its holdings by 151%. Congress Asset Management Co. also expanded its position, making the stock its 23rd largest holding.

On the clinical front, the company is seeing momentum in its obesity and oncology sectors. Data for the oral GLP-1 candidate Foundayo indicated superior weight loss and blood-sugar control compared to oral semaglutide in type 2 diabetes adults. Additionally, the FDA granted orphan-drug designation to the experimental cancer treatment olomorasib for pancreatic cancer and expanded the approval of Jaypirca for first-line CLL/SLL.

Financially, the company reported 48% revenue growth in Q2, driven largely by Mounjaro and Zepbound. While the stock has experienced recent volatility, analysts maintain a positive outlook based on strong free cash flow and expanded guidance for 2026.

Entities

Congress Asset Management Co. · Eli Lilly and Company · FDA · RVW Wealth LLC · Violich Capital Management Inc.